menu
    • menu

    Company profile for Oncoinvent

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The company’s founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed Oncoinvent to explore and develop multiple technological avenues before selecting the company’s first lead product candidate. Oncoi...
    The company’s founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed Oncoinvent to explore and develop multiple technological avenues before selecting the company’s first lead product candidate. Oncoinvent has built a Class B production and lab facility for radiopharmaceuticals. The facility received a GMP certificate from the Norwegian Medical Agency in February of 2019.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OncoinventNorway Flag
    Country
    Country
    Norway
    Address
    Address
    Gullhaugveien 7 0484 Oslo
    Telephone
    Telephone
    +47 22 18 33 05
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oncoinvent.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncoinvent-as/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oncoinvent Expands Radspherin Patent Protection
    Oncoinvent Expands Radspherin Patent Protection

    19 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-19/oncoinvent-secures-new-patent-expanding-protection-for-radspherin

    PHARMIWEB
    19 Mar 2026
    Share Share
    Oncoinvent ASA: Second half 2025 results
    Oncoinvent ASA: Second half 2025 results

    26 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oncoinvent-asa-second-half-2025-results-302697978.html

    PR NEWSWIRE
    26 Feb 2026
    Share Share
    Oncoinvent: Positive 24-Month Radspherin Data in Ovarian Cancer
    Oncoinvent: Positive 24-Month Radspherin Data in Ovarian Cancer

    17 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-17/oncoinvent-to-present-positive-24-month-follow-up-data-from-phase-1-ovarian-cancer-study-of-radspherin-at-esgo-2026

    PHARMIWEB
    17 Feb 2026
    Share Share
    Oncoinvent Expands Phase 2 Trial With Four New Recruitment Sites
    Oncoinvent Expands Phase 2 Trial With Four New Recruitment Sites

    29 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-29/four-additional-sites-open-for-recruitment-in-oncoinvent-s-phase-2-trial

    PHARMIWEB
    29 Jan 2026
    Share Share
    Oncoinvent Announces Phase 1 Radspherin Results in Ovarian Cancer
    Oncoinvent Announces Phase 1 Radspherin Results in Ovarian Cancer

    11 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-11/oncoinvent-announces-publication-of-phase-1-study-results-for-radspherin-in-ovarian-cancer-in-gynecologic-oncology

    PHARMIWEB
    11 Dec 2025
    Share Share
    Oncoinvent Releases Positive Phase 1 Radspherin to Treat Cancer
    Oncoinvent Releases Positive Phase 1 Radspherin to Treat Cancer

    08 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oncoinvent-reports-positive-final-data-from-phase-1-trial-of-radspherin-to-treat-ovarian-cancer-302577945.html

    PR NEWSWIRE
    08 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search